Sathyanarayanan Anita, Mueller Tamara T, Ali Moni Mohammad, Schueler Katja, Baune Bernhard T, Lio Pietro, Mehta Divya, Baune Bernhard T, Dierssen Mara, Ebert Bjarke, Fabbri Chiara, Fusar-Poli Paolo, Gennarelli Massimo, Harmer Catherine, Howes Oliver D, Janzing Joost G E, Lio Pietro, Maron Eduard, Mehta Divya, Minelli Alessandra, Nonell Lara, Pisanu Claudia, Potier Marie-Claude, Rybakowski Filip, Serretti Alessandro, Squassina Alessio, Stacey David, van Westrhenen Roos, Xicota Laura
Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Kelvin Grove, Queensland 4059, Australia.
Institute for Artificial Intelligence and Informatics in Medicine, TU Munich, 80333 Munich, Germany.
Eur Neuropsychopharmacol. 2023 Apr;69:26-46. doi: 10.1016/j.euroneuro.2023.01.001. Epub 2023 Jan 25.
To study mental illness and health, in the past researchers have often broken down their complexity into individual subsystems (e.g., genomics, transcriptomics, proteomics, clinical data) and explored the components independently. Technological advancements and decreasing costs of high throughput sequencing has led to an unprecedented increase in data generation. Furthermore, over the years it has become increasingly clear that these subsystems do not act in isolation but instead interact with each other to drive mental illness and health. Consequently, individual subsystems are now analysed jointly to promote a holistic understanding of the underlying biological complexity of health and disease. Complementing the increasing data availability, current research is geared towards developing novel methods that can efficiently combine the information rich multi-omics data to discover biologically meaningful biomarkers for diagnosis, treatment, and prognosis. However, clinical translation of the research is still challenging. In this review, we summarise conventional and state-of-the-art statistical and machine learning approaches for discovery of biomarker, diagnosis, as well as outcome and treatment response prediction through integrating multi-omics and clinical data. In addition, we describe the role of biological model systems and in silico multi-omics model designs in clinical translation of psychiatric research from bench to bedside. Finally, we discuss the current challenges and explore the application of multi-omics integration in future psychiatric research. The review provides a structured overview and latest updates in the field of multi-omics in psychiatry.
过去,为了研究精神疾病与健康,研究人员常常将其复杂性分解为各个子系统(例如,基因组学、转录组学、蛋白质组学、临床数据),并独立探索这些组成部分。高通量测序技术的进步和成本的降低导致数据生成量空前增加。此外,多年来越来越明显的是,这些子系统并非孤立运作,而是相互作用以驱动精神疾病与健康状况。因此,现在对各个子系统进行联合分析,以促进对健康与疾病潜在生物学复杂性的整体理解。随着可用数据的不断增加,当前的研究致力于开发新方法,这些方法能够有效地整合信息丰富的多组学数据,以发现具有生物学意义的生物标志物用于诊断、治疗和预后评估。然而,该研究的临床转化仍然具有挑战性。在这篇综述中,我们总结了通过整合多组学和临床数据来发现生物标志物、进行诊断以及预测结果和治疗反应的传统及最新的统计和机器学习方法。此外,我们描述了生物模型系统和计算机多组学模型设计在精神科研究从实验室到床边的临床转化中的作用。最后,我们讨论当前面临的挑战,并探索多组学整合在未来精神科研究中的应用。这篇综述提供了精神科多组学领域的结构化概述和最新进展。
Eur Neuropsychopharmacol. 2023-4
Adv Cancer Res. 2024
Comput Biol Med. 2023-10
Proteomics. 2024-6
PLoS Comput Biol. 2020-4-2
Genome Med. 2024-1-18
Brief Bioinform. 2024-7-25
Genom Psychiatry. 2025-3
Int J Mol Sci. 2025-4-30
Transl Psychiatry. 2025-4-6
Microb Biotechnol. 2025-3
Brain Behav Immun Health. 2024-11-9
Mol Psychiatry. 2025-2